12 November 2020 
EMA/CHMP/540606/2020  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Tivicay 
dolutegravir 
On 12 November 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Tivicay. The marketing authorisation holder for this medicinal product is ViiV Healthcare B.V.. 
The CHMP adopted a new pharmaceutical form and strength – dispersible tablets, 5 mg – together with a 
new indication as follows: 
Tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment 
of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children of at least 4 
weeks of age or older and weighing at least 3 kg. 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
